Hepatitis B is a viral infection of the liver. Untreated hepatitis B infection leads to scaring of the liver, cancer and liver failure, in extreme cases. Hepatitis B is dangerous because it is easily transmitted from infected mothers to the infant, prenatally. In 2015, the death toll from hepatitis B infection was an alarming 8,87,000.
Hepatology, as a research field has witnessed a significant growth in producing scientific literature. AASLD ( American Association for the Study of Liver Diseases) provides official recommendations for hepatitis B treatment in children and adults. Unlike the other guidelines, the AASLD guideline for hepatitis B was specifically designed in compliance with Institute of Medicine (IoM) standards. The approach used here is the Grading of Recommendation Assessment, Development and Evaluation (GRADE).
AASLD 2018 guidelines for hepatitis B complements the earlier guideline from 2016. Updates in the latest guidelines provisions the inclusion of treatments notably the use of a nucleotide reverse transcriptase inhibitor; guidance on prevention, counselling and screening; supervision of untreated patients; hepatitis B treatment in special population with coinfections, immunosuppressants treatments and transplant patients. Health care providers benefit tremendously by using these preferred approaches for diagnosis, prevention and therapeutic care of patients with Chronic Hepatitis B (CHB).
Guidance provided by AASLD on hepatitis B is supported by data on screening, prevention, clinical management and diagnosis of patient suffering from hepatitis B. Such guidelines are important because they provide expert opinion and recommendations based on scientific evidence on the best approach towards clinical management. The data consulted here are systemic reviews assessed by a multidisciplinary expert panel in terms of quality and strength using the GRADE system. The general guidance provided here influences the clinical consideration in choosing a suitable course of action.
CMEMaster - your partner in improved patient care, understands the importance of diagnosing Hepatitis B at an early stage for better treatment and hence we bring you this course from eminent faculty Dr. Kris V. Kowdley,MD,FACP,FACG,FASGE,AGF, Clinical Professor of Medicine at the University of Washington and Dr. Steven - Huy Han,MD,AGF,FAASLD ,Director,Hepatology Clinical Research Center, California, Los Angeles. Learn more about the course https://www.cmemaster.com/p/hepatitis-b-virus-read...